Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Bacterial Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Bacterial Infections
    TopAbstracts in Bacterial Infections 11/23/2009 - (DGNews)
    Genotypes of Patients With Helicobacter pylori Infection May be More Associated With Related Gastric Diseases Than Variants: Presented at ASCP - (DGDispatch)
    TopAbstracts in Bacterial Infections 11/09/2009 - (DGNews)
    Methicillin-Resistant Staphylococcus aureus Strain Linked to High Mortality Rates: Presented at IDSA - (DGDispatch)
    Study Examines Associations Between Antibiotic Use During Pregnancy, Birth Defects - (DGNews)

    News archive

     Recent webcasts/CME - Bacterial Infections
      Drug-Resistant TB
      Peritoneal Tuberculosis: Modern Peril for an Ancient Disease
      Infectious Complications of Biologic Therapies: Preventive and Therapeutic Strategies
      Relative Risks of Serious Bacterial and Opportunistic Infections Among Biologics: Results of Randomized Trials and Observational Studies
      Importance of Assessing Immunocompetence in Biologic Drug Development

      Webcasts/CME archive

       Recent cases - Bacterial Infections
        Liver Abscess And Sepsis With Bacillus Pantothenticus In An Immunocompetent Patient: A First Case Report
        Something Fishy
        Renal Amyloidosis in Whipple Disease: A Case Report
        A 72-Year-Old Man with a Rapidly Progressive Sepsis Caused by a Rare But Life-Threatening Infection
        A Rare Case of Cervical Tuberculosis Simulating Carcinoma Cervix: A Case Report

        Cases archive
          




        my personal edition > bacterial infections > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Efficacy of Tigecycline Compared to Levofloxacin for Treating Streptococcus Pneumoniae Bacteraemia in Patients With Community-Acquired Pneumonia: Presented at ECCMID-ICC

        By Chris Berrie

        MUNICH, GERMANY -- April 5, 2007 -- The first-in-class glycylcycline agent, tigecycline, appears safe and shows a clinical cure rate that is similar to the fluoroquinolone levofloxacin in hospitalised patients with community-acquired pneumonia (CAP), according to results from a combined analysis from 2 multicentre, double-blind, randomised phase 3 studies.

        Further, in the patients with CAP and Streptococcus pneumoniae bacteraemia, tigecycline achieved clinical cure rates similar to those seen in tigecycline-treated patients without bacteraemia, a researcher reported here at the joint 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress on Chemotherapy (ECCMID-ICC).

        Natalie Dartois, MD, study medical monitor and director, infectious diseases and cardiovascular metabolism, Wyeth Research, Paris, France, presented the results on April 1st.

        "Tigecycline has been registered for patients with complicated skin/skin structure infection and intra-abdominal infection, and so we have continued with the lung as we know it has good tissue penetration," Dr. Dartois said.

        Similarly, as CAP is ranked the fourth most common cause of death in the United Kingdom, and S. pneumoniae the most commonly encountered cause of CAP in both the outpatient and inpatient settings, tigecycline appears a promising agent for the targeting of pneumonia pathogens.

        Patients with CAP who exhibit S. pneumoniae bacteraemia frequently have more severe disease and increased mortality rates than those with CAP without bacteraemia. Therefore, these 2 studies were designed to compare the efficacy and safety of tigecycline and levofloxacin in a subset of hospitalised patients with CAP with and without pneumococcal bacteraemia.

        The main inclusion criteria were age 18 years or more, hospitalisation with CAP, and intravenous antibiotic treatment. Patients had to have at least 2 other indicated symptoms associated with CAP. A standard series of exclusion criteria also needed to be satisfied.

        Following randomisation, the tigecycline group received an IV dose of 100 mg, and then 50 mg IV every 12 hours. The levofloxacin group received an IV dose of 500 mg either every 12 or 24 h.

        The clinical response in these patients was evaluated as the test-of-cure (TOC), 7 to 23 days after therapy was completed. Clinical cure criteria were the following: improvement or resolution of all signs and symptoms of pneumonia present at enrolment; chest radiographs not worsened; no further need for treatment of pneumonia; no worsening or reappearance of new signs or symptoms.

        In the 2 studies combined, 846 patients received at least 1 dose of study drug, and the results were presented for both the microbiologically evaluable (ME; n = 345) and the microbiological modified intent-to-treat population (m-mITT; n = 457). For the former, 11.6% had S. pneumoniae bacteraemia, with the equivalent in the m-mITT population showing at 10.9% of patients.

        For the m-mITT patient population with pneumococcal bacteraemia, tigecycline satisfied the clinical cure criteria in 81.5% of 27 cases, as compared with levofloxacin at 65.2%.

        In comparison, the m-mITT patient population without pneumococcal bacteraemia achieved cure rates of 85.7% in 189 patients and 87.2% of 203, respectively. Therefore, with the tigecycline treatment only, the cure rate of the bacteraemia patient population was similar to that for the non-bacteraemia patient population.

        The researchers also noted that the minimum inhibitory concentrations (MICs) for tigecycline and levofloxacin for S. pneumoniae blood isolates ranged were 0.03-0.12 microg/mL and 0.5-1.0 microg/mL, respectively.

        Respective rates of discontinuations due to adverse events in the 2 treatment groups were 6.1% and 8.3%; the safety data from these 2 combined studies was similar between tigecycline and levofloxacin, Dr. Dartois said.

        Overall, tigecycline and levofloxacin appeared safe and achieved similar cure rates in these hospitalised patients with CAP, she said.

        For the S. pneumoniae bacteraemia subset, however, Dr. Dartois noted, "We can see that with tigecycline there is a very good cure rate even in the bacteraemia patients, and this is really important and interesting because we know that the serum level of tigecycline is high. So it is very good to know that we had some good results in these patients."

        Levofloxacin did not achieve these results in bacteraemia patients, she added, which suggests that empiric tigecycline may be a preferable treatment option for these hospitalised patients with CAP who require intravenous antibiotic therapy.

        This study was supported by an educational/research grant from Wyeth.


        [Presentation title: Efficacy of Tigecycline (TGC) Compared to Levofloxacin (LEV) for Treating Streptococcus Pneumoniae Bacteraemia in Patients (Pts) Hospitalised With Community-Acquired Pneumonia (CAP). Abstract P848]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send